A distinguished healthcare leader, Michael Dale currently serves as Chief Executive Officer and member of the Board of Directors for Axogen, Inc. (NASDAQ: AXGN), a global leader dedicated to the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. As an accomplished medical device executive, Mr. Dale has over 35 years of experience leading transformative, high-technology medical device companies in the cardiovascular, neuromodulation, diabetes, and electrophysiology markets. His past executive leadership roles span both public and private medical device companies, including Abbott Structural Heart, GI Dynamics, Helical Solutions, ATS Medical, Endocardial Solutions, Cyberonics, St. Jude Medical, and American Edwards Laboratories. Mr. Dale has been an active director and advisor, serving on the boards of Preceptis Medical, Enpath Medical, Rhythmia Medical, Neuronetics, Inc., NeoChord, the Advanced Medical Technology Association (AdvaMed), the St. Mary’s University Council of Regents for the School of Graduate and Professional Programs, and the University of Minnesota Carlson School of Management Medical Industry Leadership Institute. At present, he serves on the advisory board of Purdue University’s Weldon School of Biomedical Engineering, and California Polytechnic State University’s Center for Innovation & Entrepreneurship as Student Mentor. Mr. Dale holds a Bachelor of Science degree from California Polytechnic State University in San Luis Obispo, California.

Stacy Arnold has served as Vice President, Product Development & Clinical Research since January 2024 leading new product development, program management, and the clinical organization. Ms. Arnold brings more than 18 years of diverse R&D, Clinical, PMO, and business experience in the biotechnology industry. She joined Axogen in April 2018 as Vice President, Program Management. In 2019, Ms. Arnold was appointed Vice President, Clinical Research where she led the research, development, and execution of clinical strategies to strengthen and advance the body of scientific evidence of new technologies and clinical applications to restore nerve function and quality of life to patients with peripheral nerve injuries. Prior to joining Axogen, Ms. Arnold most recently served as Senior Director of R&D and Program Management at Artivion (formerly CryoLife) driving global innovation and new product development of medical devices, biologics, and tissue technologies, while leading successful program management processes and business strategies to drive growth and deliver shareholder value. Prior to 2006, Stacy held technical and leadership roles at Safe Alert Technologies. Ms. Arnold serves as a Board Member on Mercer University’s National Engineering Advisory Board. She has an M.S. in Engineering from University of Toledo and a B.S. in Biomedical Engineering from Mercer University. She also holds a global Project Management Professional License from the Project Management Institute.

Mr. DeVinney joined Axogen in April of 2007. During his tenure, he has held positions of progressive responsibility in Clinical Research, Research and Development, Product Development, Medical Education, and Medical Affairs. Mr. DeVinney has more than 16 years of experience driving innovation in peripheral nerve injury diagnosis and repair, including clinical and regulatory development strategies, portfolio development, and scientific thought leadership. He has a diverse background, including academic research and the development of tissue technologies, medical devices, pharmaceuticals, and biologics. Mr. DeVinney has been involved in research at the Virginia Commonwealth University Medical College of Virginia Hospitals, University of Utrecht, National Clinical Research, PRA International, and Angiotech. He has been involved in the successful submission of eight IDE or NDA applications, as well as numerous 510(k)s. Mr. DeVinney also serves as a Board Member for the Global Nerve Foundation. He has a B.S. degree in Chemistry from Virginia Commonwealth University.

Mr. Kemp joined Axogen in February of 2023 and brings more than 16 years of Sales, Business Development and Marketing experience from the medical device industry to the company. Prior to joining Axogen from 2013-2023, he served as Vice President of Marketing for Ambu Inc where he led Ambu’s marketing efforts to create the single use endoscopy market across multiple clinical applications. Following Ambu’s acquisition of King Systems in 2012, Mr. Kemp developed and scaled the US marketing function with new capabilities in Health Economics and Market Access, Market Development and Digital Marketing. From 2006-2009 Mr. Kemp was based in Copenhagen Denmark where he served as Corporate Business Development Manager for Ambu A/S before relocating to the US in 2009 where Mr. Kemp held the position of Vice President of Corporate Business Development until 2013. Prior to joining Ambu Mr. Kemp worked as a management consultant for 3 years with Pera Innovation working with companies across Europe. From 2001-2003, Mr. Kemp was co-founder of Mindgroup where he was responsible for Sales and Marketing of AI powered decision support systems. Mr. Kemp holds a B.A. degree in Business Administration and M. Sc. Degree in International Marketing & Management from the Copenhagen Business School.

Stacy Arnold has served as Vice President, Product Development & Clinical Research since January 2024 leading new product development, program management, and the clinical organization. Ms. Arnold brings more than 18 years of diverse R&D, Clinical, PMO, and business experience in the biotechnology industry. She joined Axogen in April 2018 as Vice President, Program Management. In 2019, Ms. Arnold was appointed Vice President, Clinical Research where she led the research, development, and execution of clinical strategies to strengthen and advance the body of scientific evidence of new technologies and clinical applications to restore nerve function and quality of life to patients with peripheral nerve injuries. Prior to joining Axogen, Ms. Arnold most recently served as Senior Director of R&D and Program Management at Artivion (formerly CryoLife) driving global innovation and new product development of medical devices, biologics, and tissue technologies, while leading successful program management processes and business strategies to drive growth and deliver shareholder value. Prior to 2006, Stacy held technical and leadership roles at Safe Alert Technologies. Ms. Arnold serves as a Board Member on Mercer University’s National Engineering Advisory Board. She has an M.S. in Engineering from University of Toledo and a B.S. in Biomedical Engineering from Mercer University. She also holds a global Project Management Professional License from the Project Management Institute.

Mr. Kemp joined Axogen in February of 2023 and brings more than 16 years of Sales, Business Development and Marketing experience from the medical device industry to the company. Prior to joining Axogen from 2013-2023, he served as Vice President of Marketing for Ambu Inc where he led Ambu’s marketing efforts to create the single use endoscopy market across multiple clinical applications. Following Ambu’s acquisition of King Systems in 2012, Mr. Kemp developed and scaled the US marketing function with new capabilities in Health Economics and Market Access, Market Development and Digital Marketing. From 2006-2009 Mr. Kemp was based in Copenhagen Denmark where he served as Corporate Business Development Manager for Ambu A/S before relocating to the US in 2009 where Mr. Kemp held the position of Vice President of Corporate Business Development until 2013. Prior to joining Ambu Mr. Kemp worked as a management consultant for 3 years with Pera Innovation working with companies across Europe. From 2001-2003, Mr. Kemp was co-founder of Mindgroup where he was responsible for Sales and Marketing of AI powered decision support systems. Mr. Kemp holds a B.A. degree in Business Administration and M. Sc. Degree in International Marketing & Management from the Copenhagen Business School.

Mr. Naor has over 20 years of global work experience as a senior finance executive in public and private pharma, biotech, and medtech companies. He managed organizations with up to $2.5 billion in sales and built top-performing finance & accounting, IR, legal, contracting & pricing, IT, and big data analytics functions. Amongst his roles, Mr. Naor has served as the Chief Financial Officer of Arbor Pharmaceuticals and supported its strategic pivot. He was also the CFO US / Americas of Mölnlycke Healthcare, where he played a pivotal role in its growth and profitability improvement and was the founder of UCB’s global Portfolio Management and Resource Allocation function, as well as the company’s US Chief Financial Officer. Earlier in his career, he held several finance leadership positions with AstraZeneca, served as a financial consultant and investment banker, worked as an auditor with KPMG, and prior to that practiced commercial law. He continues to advise and serve as a board member for emerging life sciences and technology companies. Mr. Naor holds a Master of Business Administration from IMD Business School in Switzerland, a master’s degree in law (LL.M.) from Hamburg University in Germany, and bachelor’s degrees in law (LL.B.) and in accounting from the Tel-Aviv University in Israel. Mr. Naor is also a CFA® charterholder.